Particle.news
Download on the App Store
12 ARTICLES
·
4w ago

GLP-1 Drugs Like Ozempic Linked to Lower Dementia Risk in New Studies

Recent research highlights a significant reduction in Alzheimer's and dementia risk for type 2 diabetes patients using GLP-1 receptor agonists, while emphasizing the need for further trials.

Research indicates that diabetes drugs like Ozempic may reduce the risk of Alzheimer's by protecting brain health.
Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk of cognitive decline in people with Type 2 diabetes.
Stock image of a woman holding a semaglutide injector.
Image

Overview

  • Two studies published in JAMA Neurology found that GLP-1 receptor agonists, such as Ozempic and Wegovy, are associated with a lower risk of dementia in type 2 diabetes patients.
  • A meta-analysis of 26 trials involving over 160,000 participants showed GLP-1 drugs reduced dementia risk by approximately 45%, while evidence for SGLT2 inhibitors remains mixed.
  • Researchers suggest the neuroprotective effects of GLP-1 drugs may stem from reduced inflammation and improved cardiovascular health, beyond their blood sugar control benefits.
  • The findings are limited to type 2 diabetes patients, with experts calling for large-scale trials to explore potential benefits for non-diabetic populations and confirm long-term effects.
  • While promising, the studies underscore the need for further research to establish the safety and efficacy of GLP-1 drugs for dementia prevention.